Skip to main content

Table 2 Grade 2–4 Treatment-Related AEs through Week 48 by Baseline CD4 Cell Count (cells/mm3), n (%).

From: Efficacy and safety by baseline HIV-RNA and CD4 count in treatment-naive patients treated With atazanavir/r and lopinavir/r in the CASTLE study

 

ATV/r

   

LPV/r

   

As-treated

<50

50–<100

100–<200

≥200

<50

50–<100

100–<200

≥200

 

n = 59

n = 45

n = 106

n = 222

n = 47

n = 29

n = 133

n = 224

Any

12 (20)

9 (20)

22 (21)

71 (32)

19 (40)

7 (24)

35 (26)

65 (29)

Jaundice

1 (2)

0

2 (2)

12 (5)

0

0

0

0

Diarrhea

0

1 (2)

3 (3)

6 (3)

8 (17)

3 (10)

12 (9)

26 (12)

Nausea

2 (3)

0

6 (6)

9 (4)

5 (11)

2 (7)

9 (7)

16 (7)